Articles tagged with Carcinoma
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
Researchers identified new biological markers and pathways to develop improved therapies for endometrial cancer. The study found that in-frame indels in the PIK3R1-AKT pathway promote tumor growth and provide potential targets for controlling or stopping cancer progression.
A new AI software has achieved a 100% detection rate for melanoma, significantly improving skin cancer detection accuracy. The software correctly identified 99.5% of all skin cancers and 92.5% of pre-cancerous lesions, with potential to reduce face-to-face consultations and enhance dermatology triage.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
A new size threshold for retropharyngeal lymph nodes is proposed to improve risk stratification and treatment decisions in patients with nasopharyngeal carcinoma. Using a 6-mm threshold, the study found significant differences in overall survival between stage-I and stage-II disease.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
Researchers identified distinct genomic characteristics that impact prognosis for patients with triple negative apocrine carcinoma. The study confirmed a five-year disease-free survival rate of 92.2% for these patients, significantly higher than those diagnosed with other types of TNBC.
A new study shows that estrogen receptor (ER) expression in ductal carcinoma in situ (DCIS) is multi-clonal, meaning it varies across different cells. This finding has significant clinical implications, as it may help avoid overtreatment and undertreatment in DCIS patients.
Researchers developed a reinforcement learning model that incorporates human decision-making criteria to improve AI accuracy in skin cancer diagnoses. The study showed increased sensitivity for melanoma and basal cell carcinoma, leading to more accurate diagnoses and optimal treatment decisions.
Researchers have discovered how MCV initiates DNA replication in host cells, allowing the virus to make hundreds of new copies of itself. This process is different from normal cellular DNA replication and can lead to cancer if not controlled.
Researchers found that healthy breast adipocytes secrete IGFBP2, which acts as a barrier against invasive breast cancer progression. Lower IGFBP2 levels with age may contribute to increased breast cancer risk.
A study published in the Journal of the American Academy of Dermatology found that curettage and cryosurgery is an effective and safe treatment method for basal cell carcinoma. The procedure involves scraping the lesion with a curette followed by freezing, resulting in good outcomes with minimal side effects.
The study shows that zolbetuximab delays tumor progression and improves overall survival by 25% compared to chemotherapy alone. Patients with CLDN18.2-positive tumors responded well to the treatment, indicating a new clinically relevant biomarker for gastric cancer.
The LY6 gene family has been found to be overexpressed in uterine corpus endometrial carcinoma (UCEC), leading to poor patient survival. Several LY6 genes have been identified as potential tumor-associated antigens and biomarkers for UCEC detection and prognosis.
Researchers developed a method to predict DCIS progression to invasive breast cancer using mice with human DCIS cells. The study found molecular similarities between humans and mice, including the presence of HER2 protein increasing breast cancer risk.
Researchers discuss the importance of biomarkers in breast lump management, enabling patients to make informed decisions between proactive treatment and watchful waiting. The development of biomarkers could provide personalized risk assessments and guide treatment strategies for women with breast lumps.
An international study of 1,044 patients with head and neck squamous cell carcinoma found that combining radiotherapy with chemotherapy significantly improves survival rates compared to radiotherapy alone. The benefit was particularly notable in patients between 65-79 years old with good general health.
The USPSTF finds the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer. Skin cancer is the most commonly diagnosed cancer in the U.S., with melanomas causing the most skin cancer deaths.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
A comprehensive analysis of invasive ER+ breast cancers found macrophages as dominant immune cells infiltrating tumors. The study identified distinct immune cell 'neighborhoods' associated with good patient outcomes and highlights the need for tailored immunotherapies targeting macrophages.
A recent study suggests that routine evaluation of HER2 expression in ductal carcinoma in situ (DCIS) is crucial to avoid under or overtreatment. The research found a significant association between HER2 overexpression and a higher risk of recurrence, as well as improved radiotherapy outcomes.
Ultrafast MRI provides beneficial information for predicting DCIS upgrade to invasive cancer, including time to enhancement and lesion size. A study found that UF-MRI can accurately predict lesions diagnosed as DCIS at percutaneous biopsy that will be upgraded to invasive cancer at surgery.
Researchers from prominent institutions discuss hepatocellular carcinoma's pathogenesis, genomic heterogeneity, and targeted therapy options. The review aims to characterize HCC's complexities and develop clinically relevant biomarkers for better management.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
For adrenal lesions evaluated by single-phase dual-energy CT, fat fraction had significantly higher sensitivity than virtual noncontrast attenuation at both clinically optimal threshold and traditional ≤10 HU threshold. Fat fraction-derived metrics can help definitively diagnose incidental adrenal lesions as adenomas.
Researchers at Goethe University Frankfurt found that dying colon cancer cells release ATP to neighboring tumor cells, activating a survival signaling pathway. Interrupting this communication can significantly increase the effectiveness of chemotherapy against resistant tumors.
Researchers at Clinica Universidad de Navarra found that ultrasound-guided surgery (IOUS) is more effective and quicker than traditional wire-localisation methods for treating ductal carcinoma in situ (DCIS). This technique reduces the risk of positive margins, a common cause of second operations.
Researchers identified genes associated with aggressive clear cell renal carcinoma, a subtype of kidney cancer. Anticoagulant therapies may enhance cancer treatment efficacy. Specific genes involved in blood clotting and insulin transport were found to be linked to disease progression.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.
The PROSPER RCC trial showed no difference in recurrence-free survival between arms, with higher adverse events reported in the nivolumab arm. The trial's results inform future research on neoadjuvant trials in high-risk renal cell carcinoma.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.
A prospective study compared CEM and MRI for NAT response assessment in patients with breast cancer. CEM yielded comparable assessments of lesion size and RECIST categories as MRI, but with lower sensitivity for pathologic complete response. Delayed CEM acquisition detected residual ductal carcinoma in situ (DCIS).
The study reveals a narrowing gap between cancer profiles in China and the USA, with converging trends in lung, breast, and colorectal cancers. China's cancer burden is expected to rise, while the US has seen reduced rates since the 1990s due to effective prevention strategies.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
A phase II clinical trial of remetinostat gel found a 69.7% response rate to the topical treatment, with complete responses observed across multiple BCC subtypes, and a durable response in nodular BCCs.
Cells undergoing EMT promote tumor growth by acquiring an endothelial phenotype or contributing to vascular transdifferentiation. FOXC2 is crucial for these processes.
Researchers at Jiangnan University developed a sensing platform to detect microRNA-205, a potential biomarker for radiation-resistant nasopharyngeal carcinoma. The method shows high sensitivity and excellent selectivity, enabling detection of miR-205 with a limit of detection of 4.78 nM.
Researchers from Queen Mary University of London confirmed the role of oestrogen receptor biomarker in ductal carcinoma in situ and developed a new, more accurate method to predict long-term outcomes. The study found ER expression is a strong prognostic factor for recurrence in DCIS.
Researchers discovered that a high proportion of advanced carcinomas carry a mutant form of the Siglec-XII protein, which is rarely expressed in normal humans. This finding may explain why humans are more prone to aggressive cancers compared to chimpanzees.
A new genetic test identifies patients with invasive lobular carcinoma (ILC) at high risk of recurring and progressing. The 70-gene signature test showed that ILC patients whose genetic make-up puts them at high risk may benefit from additional adjuvant therapy.
Researchers found GATA3 and APOBEC3B overexpressed in adrenocortical carcinoma, regulating cell proliferation and DNA damage. Their expression levels are linked to patient survival, providing novel insights into ACC prognosis.
A new study by Flinders University researchers found that antibiotic use is directly associated with worse survival rates in patients with urothelial carcinoma treated with atezolizumab. The study suggests antibiotics may specifically reduce the effectiveness of cancer immunotherapies, highlighting a need for extra caution when using t...
A new study identifies key genes driving fibrolamellar carcinoma, a rare and deadly liver cancer. Researchers developed a cell model to test combination therapy strategies, including inhibitors of genes SLC16A14 and CA12, which showed promising results in killing tumor cells.
A study published in BJS Open found that mortality rates from colorectal cancer surgery are significantly higher in smaller hospitals with lower annual case numbers. Hospitals performing more operations per year have better patient survival rates, likely due to increased access to specialized care and equipment.
A new study from Northwestern Medicine reports the first guidelines for treating sebaceous carcinoma, a cancer of oil glands that can be found on the skin or in the eye. The guidelines provide clear direction for treating these tumors, which may result in fewer deaths.
Researchers have discovered fullerene compounds that can effectively kill non-small-cell lung carcinoma cells without harming healthy cells. The anti-tumor activity of these compounds has great potential for the development of new treatments for this aggressive form of cancer.
Researchers found that Medicare Advantage beneficiaries had higher 30-day risk-adjusted readmission rates than traditional Medicare beneficiaries for three common medical conditions. Despite previous studies suggesting better post-acute care outcomes for Medicare Advantage enrollees, the study found no evidence of improved readmission ...
A combination of ipilimumab and nivolumab demonstrated clinical benefit among patients with high-grade neuroendocrine carcinoma in a phase II clinical trial. The therapy showed an overall response rate of 24% and improved progression-free survival, offering new hope for this patient population.
A new diagnostic technique using infrared imaging and proteomics has identified a protein biomarker called AHNAK2 that can accurately distinguish between bladder cancer and benign inflammation. The technique has been shown to have high sensitivity and specificity in differentiating between various stages of bladder cancer.
Pembrolizumab, a new immunotherapy drug, shows lasting tumor control and improved overall survival in advanced Merkel cell carcinoma patients. The study reports generally manageable side effects and supports the use of immunotherapy as an effective treatment option for this aggressive form of skin cancer.
A study led by Johns Hopkins Medicine found that immunotherapy drug pembrolizumab is more effective than traditional chemotherapy for patients with aggressive Merkel cell carcinoma. The treatment showed high response rates and durable progression-free survival in both virus-positive and virus-negative subtypes.
A new BJS study found axillary ultrasound imaging to be less sensitive for detecting axillary metastatic lymph nodes in women with invasive lobular carcinoma compared to invasive ductal carcinoma. Women with invasive lobular carcinoma may benefit from axillary biopsies regardless of ultrasonographic appearance.
Early clinical studies with BET inhibitors and EZH2 inhibitors have shown remarkable activity in patients with lymphoma, including diffuse large B-cell lymphoma and NUT carcinoma. Tolerability has been generally good, but side effects such as thrombocytopaenia and fatigue have emerged.
Researchers at Mayo Clinic are testing a vaccine that aims to establish lifelong immunity against precancerous breast lesions. The vaccine targets human epidermal growth factor 2 (HER-2) and has shown promise in a phase I clinical study, eliciting an immune response in all tested individuals.
Researchers found that women with ductal carcinoma in situ (DCIS) are at a slightly lower risk of dying from any cause compared to the general population. After 10 years, DCIS patients had a 2.5% risk of dying from breast cancer and a 10% lower overall mortality rate.